Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amantadine ER in Parkinson's Disease with Levodopa-Induced Dyskinesia
NCT02153645Phase 3Terminated
- Start
- Aug 2014
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of amantadine in levodopa-induced dyskinesia (LID) (3 arms). Primary endpoint: Unified Dyskinesia Rating Scale at Day 98. Started Aug 2014; status: terminated.
02
Drugs
amantadine
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT02153645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02153645.